TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01509456

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Bicarbonate
Description: 90 mmol daily, effervescent tablets 30 mmol diluted in 200 ml tab water supplemented three times a day together with the main meals for 21 days of HDT- bedrest
Study: NCT02495233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: oral
Study: NCT01029964

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individually and in groups
Description: During three year in a clinical setting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individually and in groups
Description: During three year in a clinical setting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individually and in groups
Description: During three year in a clinical setting.
Study: NCT04105725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention+Substance-Free Activity Session
Description: A dialogue with the individual of their own experiences with alcohol use and related problems, as well as academic/career goals and personal interests.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol + Nutrition Education Session
Description: Education on alcohol, alcohol metabolism in the body, and alcohol overdose, as well as education on food groups and recommendations for a balanced diet.
Study: NCT03672981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo resistance training program and cardiovascular exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01873703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pracinostat
Description: Histone deacetylase inhibitor (HDACi)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azacitidine
Description: Active comparator 75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Active comparator 75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable
Study: NCT03672981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Participate in phone calls with exercise physiologist
Study: NCT02483910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct Instruction-Language for Learning (DI-LL) via telehealth (e.g., Zoom or WebEx)
Description: DI-LL is composed of up to 150 lessons (15 sets of 10 lessons each - e.g., lessons 1-10, 11-20, 21-30, etc.) that build on one another. The program uses demonstrations and pictures to expand vocabulary and teach language skills to children in manageable steps. The curriculum focuses on teaching spoken language across six areas: actions, description of objects, general information, standardized prompts (show me or point to or say the whole thing), classification, and problem-solving strategies. For example, DI-LL moves from the identification of familiar objects to the description and classification of these objects. Children learn the precise meaning of both familiar and new concepts and use these concepts in statements and questions. The DI-LL also incorporates 15 assessment tests (one for each set of 10 lessons). These assessment tests are given after each set of 10 lessons to confirm mastery of the material and the child's readiness to move on to the next set of 10 lessons.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of care delivered via telehealth (e.g., Zoom or WebEx)
Description: Usual care including speech therapy in school, community or both

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care delivered via telehealth (e.g., Zoom or WebEx)
Description: Usual care including speech therapy in school, community or both
Study: NCT00787800

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dual Chamber ICD
Description: Dual Chamber ICD: Atrial therapies and minimized ventricular pacing will be programmed on along with VT/VF detection and therapies with detection enhancements; remote monitoring set to alert for sustained atrial fibrillation Dual Chamber ICD Atrial prevention and termination therapies, Managed Ventricular Pacing (MVP)along with VT/VF detection and therapies for dual chamber device.
Study: NCT02717598

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cold snare polypectomy
Description: CSP was performed by using a disposable oval snare with a diameter of 10 mm under gentle suction to reduce colon wall tension. The tip of the endoscope was deflected toward the polyp base to ensnare 1 to 2 mm of normal mucosa surrounding the polyp. Afterward, additional EMR was performed at the polypectomy site to evaluate for the presence of residual polyp tissue,including an additional 1 to 2 mm clear margin, was resected by the snare and Endocut current after submucosal injection of a mixed solution.In the event that no tissue could be removed or if EMR failed to get in situ mucosal specimens. At least four cold biopsies using forceps on the remaining margins were obtained.After each procedure, the polypectomy site was observed for 30 seconds to confirm the absence of immediate bleeding.Cross-sections of the EMR specimens were collected at 1-mm intervals.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hot snare polypectomy
Description: HSP, which is using electrocoagulation on the basis of using cold snare.After HSP, another independent endoscopic surgeon judged whether the endoscopic eradication was successful. Afterward, additional EMR was performed at the polypectomy site to evaluate for the presence of residual polyp tissue,including an additional 1 to 2 mm clear margin, was resected by the snare and Endocut current after submucosal injection of a mixed solution.In the event that no tissue could be removed or if EMR failed to get in situ mucosal specimens. At least four cold biopsies using forceps on the remaining margins were obtained.After each procedure, the polypectomy site was observed for 30 seconds to confirm the absence of immediate bleeding, the specimens were retrieved and stored in formalin. Cross-sections of the EMR specimens were collected at 1-mm intervals; accurate tissue section of the marked site was ensured.
Study: NCT00120796

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B surface antigen
Study: NCT01803802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: Five sessions of 30 minutes of expressive writing

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Expressive writing
Description: Five sessions of 30 minutes of expressive writing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expressive writing
Description: Five sessions of 30 minutes of expressive writing
Study: NCT01568580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GreenGene
Description: Dose : 10 \~ 50IU/kg Administration method : intravenous infusion or bolus
Study: NCT00593086

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pain management
Description: Pain mamagement for burn care procedures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pain management
Description: Pain mamagement for burn care procedures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care/no virtual reality game
Description: no intervention for standard of care
Study: NCT02110108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revlite Laser System
Description: Revlite Laser System for the Treatment of Facial Solar Lentigines

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revlite Laser System
Description: Revlite Laser System for the Treatment of Facial Solar Lentigines
Study: NCT00430781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pazopanib (GW786034)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib (GW572016)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lapatinib (GW572016)
Study: NCT03713723

Intervention type: DEVICE
Intervention: NICaS bioimpedance system
Description: NICaS is a bioimpedance system focusing on noninvasive assessment and monitoring of cardiovascular, respiratory, and fluid parameters.Cardiovascular monitoring will be carried out using non-invasive NICAS cardiac impedance cardiography by the use of two electrodes stickers which are pasted on the wrists for 6 minutes
Study: NCT02658162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SANGUINATE
Description: Two (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
Study: NCT01863758

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human-cl rhFVIII
Description: Human-cl rhFVIII was provided as a freeze-dried concentrate to be reconstituted in water for injection.
Study: NCT02385032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: URSO Forte

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: URSO Forte
Study: NCT00893789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Armodafinil 50 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Armodafinil 150 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Armodafinil 250 mg/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01771679

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Bone Marrow Cells
Description: Subjects in Part 1, Cohorts 1-3 will receive a 1550 nm Fraxel laser (6-8 mJ, Level 2) treatment on the face followed by a single intravenous infusion of 0.5, 1.0, or 1.5 million mesenchymal cells per kg of body weight, not to exceed 150 million cells. Subjects in Part 2 will receive a 1550 Fraxel laser (6-8 mJ, Level 2) treatment on the face followed by a single intravenous infusion of mesenchymal cells at the Maximum Tolerated Dose, as determined by the safety results of Part 1. The dose in Part 2 is 1.5 million cells per kg, not to exceed a total of 150 million cells.
Study: NCT03893903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDH1R132H peptide vaccine
Description: The vaccine is applied by s.c. injection with 300 μg IDH1R132H peptide emulsified in 0.5 ml 33% DMSO / 0.5 ml Montanide® per dose.~Patients receive 3 doses in two week intervals for 6 weeks, followed by re-resection. 4 weeks after surgery, treatment will be resumed consisting of 5 additional vaccinations in 4 week intervals, followed by maintenance vaccines until progression in three months intervals after a pause of 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDH1R132H peptide vaccine
Description: The vaccine is applied by s.c. injection with 300 μg IDH1R132H peptide emulsified in 0.5 ml 33% DMSO / 0.5 ml Montanide® per dose.~Patients receive 3 doses in two week intervals for 6 weeks, followed by re-resection. 4 weeks after surgery, treatment will be resumed consisting of 5 additional vaccinations in 4 week intervals, followed by maintenance vaccines until progression in three months intervals after a pause of 16 weeks.
Study: NCT00787800

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single Chamber ICD
Description: Single Chamber: Optimally programmed VT/VF detection and therapies will be programmed on including use of detection enhancements.~VT/VF detection and therapies with discrimination criteria for single chamber device.
Study: NCT03468465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin Succinate
Description: 10 mg tablet daily during 75 days maximum

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro-Muscular Stimulators (NMS)
Description: Treatment with T-PTNS will include a first induction period of 4 weeks with daily sessions of 30 minutes duration and performed at each subject's home (Monday through Friday, resting weekends) and a second recall period of 2 additional months, with a session every 4 weeks that will be held at the healthcare center. In total there will be 20 sessions in the induction period and 2 in the recall period
Study: NCT00461812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advair
Study: NCT03893903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab is a humanized anti-PD-L1 antibody approved for patients with Merkel cell carcinoma and urothelial cancer. It is applied by i.v. infusion with 10 mg/kg per dose.~Patients receive 3 doses of Avelumab in 2week intervals for 6 weeks, followed by re-resection. Avelumab will be administered in monthly intervals starting 4 weeks after the surgery until progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab is a humanized anti-PD-L1 antibody approved for patients with Merkel cell carcinoma and urothelial cancer. It is applied by i.v. infusion with 10 mg/kg per dose.~Patients receive 3 doses of Avelumab in 2week intervals for 6 weeks, followed by re-resection. Avelumab will be administered in monthly intervals starting 4 weeks after the surgery until progression.
Study: NCT03996538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride Extended-Release Tablets
Description: Subjects will ingest 1500mg/day of metformin hydrochloride extended release. Immune responses will be examined prior to treatment, prior to flu vaccination, and after flu vaccination.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: All subjects will be vaccinated with high-dose influenza vaccine at the appropriate time of the year per current CDC and FDA recommendations

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Influenza Vaccine
Description: All subjects will be vaccinated with high-dose influenza vaccine at the appropriate time of the year per current CDC and FDA recommendations
Study: NCT04462848

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-SARS-CoV-2 human convalescent plasma
Description: Single transfusion. The total volume (mL) to be transfused will be based on participant weight (kg) and will be calculated as 5 mL/kg. The maximum volume to be transfused will be 500 mL.
Study: NCT02147938

Intervention type: DRUG
Intervention: Tacrolimus
Description: oral

Intervention type: DRUG
Intervention: Tacrolimus
Description: oral
Study: NCT00471380

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: travoprost 0.004% and brinzolamide 1%
Description: Group A = concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: travoprost 0.004% and brinzolamide 1%
Description: Group A = concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle
Description: group B = fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle
Description: group B = fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.).
Study: NCT00302601

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Scintigraphic interpretation
Description: Not relevant
Study: NCT02369510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose epinephrine
Description: 0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose epinephrine
Description: 0.2ml of 1:1000 epinephrine will be added to the standard spinal medications

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No epinephrine
Description: 0.2ml of preservative-free saline will be added to the standard spinal medications
Study: NCT05999942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Amikacin for Inhalation
Description: Administered via the Pari LC STAR™ nebulizer.
Study: NCT03291418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATB-346 OR Placebo
Description: Comparison of gastrointestinal effects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen sodium
Description: Comparison of gastrointestinal effects
Study: NCT02581943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT03664167

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: intensive weight loss diet, with Cambridge weightplan products, and visits to a dietician.
Description: intensive weight loss diet, with Cambridge weightplan products, and visits to a dietician.
Study: NCT04141111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Description: On each visit (baseline, 4, 8, and 12 months), participants received an iPro2 CGM device (MiniMed Medtronic), placed according to the manufacturer's standard procedure. The iPro2 was used each time for 7-days. During this period, patients were asked to perform 4 SMBG measurements daily for calibration (fasting, lunch, dinner, and before bed). Patients received a diary to register food intake, physical activity and medication, SMBG values, and any diabetes-related event (extra consultations, phone calls, etc) in the previous 4 months.~Each time, CGM data was interpreted by an expert clinician, and a report was delivered, within one week, to the respective healthcare team. This report was discussed together by the patient and one member of the healthcare team, either in consultation or by phone, agreeing on any necessary therapeutic changes. If necessary, extra consultations for nutrition, nursing, or education, were scheduled, to address specific needs identified during rCGM review.
Study: NCT03693261

Intervention type: PROCEDURE
Intervention: Coronary artery bypass grafting (CABG)
Description: CABG, as part of the standard medical care
Study: NCT02581943

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02048579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Therapy + Motivational Interviewing
Study: NCT03905447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC945
Description: Nebulized PC945 5mg OD for 28 days with an optional extended treatment period of a further 56 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care antifungal medication
Study: NCT04585139

Intervention type: DEVICE
Group type: OTHER
Intervention: Phase 1- Introduction to Dexcom G6 CGM
Description: Examine whether non-adjunctive use of CGM improves glycemic control in adults with diabetes managed by intensive insulin therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phase 1- Introduction to Dexcom G6 CGM
Description: Examine whether non-adjunctive use of CGM improves glycemic control in adults with diabetes managed by intensive insulin therapy
Study: NCT02979067

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal oxygen flow
Description: Nasal oxygen flow during apnoea
Study: NCT03872414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anterior cingulate cortex activation
Description: Functional Magnetic Resonance Imaging Participants in the experimental group will be trained using functional magnetic resonance imaging to regulation brain activity in anterior cingulate cortex.~The anterior cingulate cortex is a brain region that is known to be involved in emotion processing. Activation of this region is expected to improve emotion processing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anterior cingulate cortex activation
Description: Functional Magnetic Resonance Imaging Participants in the experimental group will be trained using functional magnetic resonance imaging to regulation brain activity in anterior cingulate cortex.~The anterior cingulate cortex is a brain region that is known to be involved in emotion processing. Activation of this region is expected to improve emotion processing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anterior cingulate cortex activation
Description: Functional Magnetic Resonance Imaging Participants in the experimental group will be trained using functional magnetic resonance imaging to regulation brain activity in anterior cingulate cortex.~The anterior cingulate cortex is a brain region that is known to be involved in emotion processing. Activation of this region is expected to improve emotion processing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primary auditory cortex activation
Description: Functional Magnetic Resonance Imaging Participants in each group will be trained using functional magnetic resonance imaging to regulation brain activity in primary auditory cortex. The primary auditory cortex is a brain region that is NOT specifically involved in emotion processing. Activation of this region is NOT expected to improve emotion processing; and thus activation of this brain region serves as control/placebo condition in the current design (placebo comparator).